Literature DB >> 4036533

Etomidate infusion and adrenocortical function. A study in elective surgery.

M Wanscher, E Tønnesen, M Hüttel, K Larsen.   

Abstract

The adrenocortical response to a short tetracosactrin (Synacthen) test was studied in 11 patients receiving either etomidate infusion or thiopentone infusion used to maintain anaesthesia for abdominal hysterectomy. Pethidine was used as the narcotic component. The results showed that etomidate infusion (median 28.5 ug/kg/min) completely blocked the adrenocortical response to corticotropin stimulation for at least 24 h after surgery. No suppression was found in patients receiving thiopentone infusion. It is concluded that etomidate cannot be recommended for routine induction and maintenance of anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4036533     DOI: 10.1111/j.1399-6576.1985.tb02238.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  5 in total

Review 1.  Clinical and molecular pharmacology of etomidate.

Authors:  Stuart A Forman
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

Review 2.  [Etomidate for intravenous induction of anaesthesia].

Authors:  C Dumps; D Bolkenius; E Halbeck
Journal:  Anaesthesist       Date:  2017-12       Impact factor: 1.041

Review 3.  Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs.

Authors:  Chaoyi Deng; Jin Liu; Wensheng Zhang
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

Review 4.  Pre-procedural Preparation and Sedation for Gastrointestinal Endoscopy in Patients with Advanced Liver Disease.

Authors:  Brian M Fung; Deanna J Leon; Lauren N Beck; James H Tabibian
Journal:  Dig Dis Sci       Date:  2021-06-24       Impact factor: 3.487

Review 5.  Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics.

Authors:  Beatrijs I Valk; Michel M R F Struys
Journal:  Clin Pharmacokinet       Date:  2021-06-01       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.